-
VKTX Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Viking Therapeutics (VKTX)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.68 mm | 26.68 mm | 26.68 mm | 26.68 mm | 26.68 mm | 26.68 mm |
Cash burn (monthly) | 7.89 mm | 2.40 mm | 15.41 mm | 12.58 mm | 10.39 mm | 7.32 mm |
Cash used (since last report) | 16.41 mm | 5.00 mm | 32.06 mm | 26.16 mm | 21.62 mm | 15.22 mm |
Cash remaining | 10.26 mm | 21.68 mm | -5.39 mm | 513.68 k | 5.05 mm | 11.46 mm |
Runway (months of cash) | 1.3 | 9.0 | -0.3 | 0.0 | 0.5 | 1.6 |
13F holders | Current |
---|---|
Total holders | 409 |
Opened positions | 77 |
Closed positions | 97 |
Increased positions | 143 |
Reduced positions | 124 |
13F shares | Current |
---|---|
Total value | 3.23 tn |
Total shares | 85.53 mm |
Total puts | 3.75 mm |
Total calls | 5.77 mm |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
FMR | 16.72 mm | $672.63 bn |
Vanguard | 10.17 mm | $409.34 bn |
BlackRock | 5.87 mm | $236.33 bn |
STT State Street | 4.93 mm | $198.20 bn |
LGND Ligand Pharmaceuticals | 3.62 mm | $55.83 mm |
MS Morgan Stanley | 2.59 mm | $104.37 bn |
JPM JPMorgan Chase & Co. | 2.16 mm | $86.82 bn |
Geode Capital Management | 1.88 mm | $75.70 bn |
Citadel Advisors | 1.49 mm | $59.76 bn |
Braidwell | 1.48 mm | $59.54 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Jan 25 | Greg Zante | Common Stock, par value $0.00001 per share | Sell | Dispose S | No | No | 43.3194 | 4,700 | 203.60 k | 165,259 |
6 Jan 25 | Greg Zante | Common Stock, par value $0.00001 per share | Sell | Dispose S | No | No | 42.6888 | 45,609 | 1.95 mm | 169,959 |
6 Jan 25 | Lian Brian | Common Stock, par value $0.00001 per share | Sell | Dispose S | No | No | 43.3169 | 19,000 | 823.02 k | 2,366,570 |
6 Jan 25 | Lian Brian | Common Stock, par value $0.00001 per share | Sell | Dispose S | No | No | 42.6838 | 175,490 | 7.49 mm | 2,385,570 |
6 Jan 25 | Marianna Mancini | Common Stock, par value $0.00001 per share | Sell | Dispose S | No | No | 43.3165 | 5,100 | 220.91 k | 374,134 |
6 Jan 25 | Marianna Mancini | Common Stock, par value $0.00001 per share | Sell | Dispose S | No | No | 42.6893 | 49,115 | 2.10 mm | 379,234 |
3 Jan 25 | Greg Zante | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 21,667 | 0.00 | 215,568 |
3 Jan 25 | Greg Zante | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 44,533 | 0.00 | 193,901 |
3 Jan 25 | Greg Zante | Stock Option Common Stock | Grant | Acquire A | No | No | 42.89 | 37,200 | 1.60 mm | 37,200 |
3 Jan 25 | Lian Brian | Common Stock, par value $0.00001 per share | Grant | Acquire A | No | No | 0 | 163,333 | 0.00 | 2,561,060 |